Comparative Pharmacology
Head-to-head clinical analysis: ERYGEL versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYGEL versus PEDIAMYCIN 400.
ERYGEL vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation of peptidyl-tRNA.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Apply a thin layer to affected areas twice daily. Topical use only.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.0–2.5 hours) after topical application, too short to accumulate with daily use.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily hepatic metabolism; less than 10% excreted renally as unchanged drug. Biliary excretion is minimal.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic